Kansikuva näyttelystä Explore Cell Therapy

Explore Cell Therapy

Podcast by National Marrow Donor Program/Be The Match

englanti

Teknologia & tieteet

Rajoitettu tarjous

3 kuukautta hintaan 7,99 €

Sitten 7,99 € / kuukausiPeru milloin tahansa.

  • Podimon podcastit
  • Lataa offline-käyttöön
Aloita nyt

Lisää Explore Cell Therapy

In Explore Cell Therapy, we dig into the latest cell and gene therapy research and best practices to help you advance care for patients with hematologic malignancies and disorders. You’ll hear interviews with well-known and up-and-coming physicians in the hematopoietic stem cell transplantation (HCT) and cell and gene therapy field. You’ll receive insights from the National Marrow Donor Program® and our partners into what it takes to connect patients to the best available therapies. In season 2, we examine practice-changing research and hot topics in HCT and other cellular therapies. You’ll hear conversations with experts who specialize in HCT and at hematology/oncology practices.

Kaikki jaksot

36 jaksot

jakson 14 - HCT Across MDS Genetic Subtypes, Part I: Expanding Access to Older Patients kansikuva

14 - HCT Across MDS Genetic Subtypes, Part I: Expanding Access to Older Patients

In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53. In Part I: Expanding Access to Older Patients, guests explore major advances in transplant for older patients with MDS, highlighting the recent expansion of coverage through the Centers for Medicare and Medicaid Services (CMS), a significant milestone driven by recent studies that demonstrate the safety and efficacy of HCT in patients over 65 years old. To read bios on the panelists and to access additional resources related to this episode, visit Our Site [https://www2.bethematchclinical.org/l/566592/2023-06-12/n41tmn].

14. tammi 2025 - 32 min
jakson 14 - HCT Across MDS Genetic Subtypes, Part II: The Role of Genetics and Early Consult kansikuva

14 - HCT Across MDS Genetic Subtypes, Part II: The Role of Genetics and Early Consult

In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53.  In Part II, experts stress the importance of early consultation to optimize treatment decisions and ensure equity in access to HCT for older patients in need of a curative treatment option.    To read bios on the panelists and to access additional resources related to this episode, visit Our Site [https://www2.bethematchclinical.org/l/566592/2023-06-12/n41tmn].

14. tammi 2025 - 31 min
jakson 13 - Optimizing Donor Searches in HCT, Part II: Overcoming Barriers kansikuva

13 - Optimizing Donor Searches in HCT, Part II: Overcoming Barriers

This two-part “Explore Cell Therapy” podcast episode dives into recent research on the benefits and challenges of optimizing donor searches for allogeneic hematopoietic cell transplant (HCT). Joseph Pidala, MD, PhD, Moffitt Cancer Center, and Jason Dehn, MPH, NMDPSM, review crucial findings from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1702 trial to shed light on the pivotal role of search prognosis in helping more eligible patients receive HCT.   In Part II: Overcoming Barriers, the experts review implications for the future of donor search optimization, transplant access and health equity in an increasingly diverse patient population.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site [https://www2.bethematchclinical.org/l/566592/2023-06-12/n41tmn].

20. marras 2024 - 26 min
jakson 13 - Optimizing Donor Searches in HCT, Part I: Strategies and Considerations kansikuva

13 - Optimizing Donor Searches in HCT, Part I: Strategies and Considerations

This two-part “Explore Cell Therapy” podcast episode dives into recent research on the benefits and challenges of optimizing donor searches for allogeneic hematopoietic cell transplant (HCT). Joseph Pidala, MD, PhD, Moffitt Cancer Center, and Jason Dehn, MPH, NMDPSM, review crucial findings from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1702 trial to shed light on the pivotal role of search prognosis in helping more eligible patients receive HCT.   In Part I: Strategies and Considerations, the experts discuss strategies to prioritize alternative donor sources to ensure that more patients receive HCT at optimal timepoints.  To read bios on the panelists and to access additional resources related to this episode, visit Our Site [https://www2.bethematchclinical.org/l/566592/2023-06-12/n41tmn].

20. marras 2024 - 25 min
Loistava design ja vihdoin on helppo löytää podcasteja, joista oikeasti tykkää
Loistava design ja vihdoin on helppo löytää podcasteja, joista oikeasti tykkää
Kiva sovellus podcastien kuunteluun, ja sisältö on monipuolista ja kiinnostavaa
Todella kiva äppi, helppo käyttää ja paljon podcasteja, joita en tiennyt ennestään.

Valitse tilauksesi

Suosituimmat

Rajoitettu tarjous

Premium

  • Podimon podcastit

  • Ei mainoksia Podimon podcasteissa

  • Peru milloin tahansa

3 kuukautta hintaan 7,99 €
Sitten 7,99 € / kuukausi

Aloita nyt

Premium

20 tuntia äänikirjoja

  • Podimon podcastit

  • Ei mainoksia Podimon podcasteissa

  • Peru milloin tahansa

30 vrk ilmainen kokeilu
Sitten 9,99 € / kuukausi

Aloita maksutta

Premium

100 tuntia äänikirjoja

  • Podimon podcastit

  • Ei mainoksia Podimon podcasteissa

  • Peru milloin tahansa

30 vrk ilmainen kokeilu
Sitten 19,99 € / kuukausi

Aloita maksutta

Vain Podimossa

Suosittuja äänikirjoja

Aloita nyt

3 kuukautta hintaan 7,99 €. Sitten 7,99 € / kuukausi. Peru milloin tahansa.